To show your support of this position statement, please send an e-mail with your intent, and affiliation to danielle.bonadies@yale.edu

Below please find the full text on a Genetic Testing Lab Position Statement that pledges we, the ordering clinicians, will continue to make laboratory and testing choices based on what is in the best interest of our patients and will not be swayed by political, personal or financial gain.

This is also an opportune time for patient organizations, clinical organizations and insurers to show their support of laboratories that will fully share past, current and future data in open databases that serve research and patient care.

Please pass this on to your family, friends, colleagues, patients and contacts within your networks.

Genetic Testing Position Statement

Cancer Genetic Counseling Program Yale School of Medicine/Yale Cancer Center

New Haven, CT February 2014

With the emergence of new testing technologies and the 2013 Supreme Court decision banning gene patenting, the available cancer genetic testing options and the laboratories offering testing have expanded exponentially and are likely to continue to do so. As providers we have a responsibility to our patients to make the best decisions regarding which laboratory to use and which tests are most appropriate based on what is best for the patients. Our decisions will not be swayed by political, personal and/or financial gain.

2. Time: How long will the patient have to wait for his or her test results?

3. Cost: Will our patients insurance carrier cover this test at this laboratory?

See the article here:

Cancer Genetic Counseling

FDA Approves Genentechs Lucentis (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema

On November 14, 2014, a Genentech medicine received FDA approval for use in a specific type of platinum-resistant ovarian cancer.

On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).

Presentations, Posters, and Papers galore. Check out our ACR 2014 newsroom to learn more about our commitment to rheumatology.

Genentech will present important new ophthalmic data at the 118th Annual Meeting of the American Academy of Ophthalmology (AAO) from October 18-21 in Chicago.

On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).

Read about Genentechs planned acquisition of Seragon.

With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline.

Genentech fully supports efforts to increase transparency around the partnership between the industry and healthcare professionals.

Medicine for people with chronic idiopathic urticaria (CIU), a form of chronic hives.

Read more here:

GENE - Genentech

UCL - MSc Cell and Gene Therapy
to find more information please visit: http://www.ucl.ac.uk/cell-gene-therapy.

By: StudyUCL

More:

UCL - MSc Cell and Gene Therapy - Video

Contact Information

Available for logged-in reporters only

Fast Facts Gene therapy may effectively treat glioma, a deadly form of brain cancer, but getting the right genes to cancer cells in the brain is difficult. For the first time, Johns Hopkins researchers used biodegradable nanoparticles to kill brain cancer cells in animals and lengthen their survival. The nanoparticles are filled with genes for an enzyme that turns a compound into a potent killer of cancer cells.

VIDEO: Programming Cancer Cells to Self-Destruct

Newswise Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist. New insights into specific gene mutations that arise in this often deadly form of brain cancer have pointed to the potential of gene therapy, but its very difficult to effectively deliver toxic or missing genes to cancer cells in the brain. Now, Johns Hopkins researchers report they have used nanoparticles to successfully deliver a new therapy to glioma cells in the brains of rats, prolonging their lives. A draft of the study appeared this week on the website of the journal ACS Nano.

Previous research on mice found that nanoparticles carrying genes can be taken up by brain cancer cells, and the genes can then be turned on. However, this is the first time these biodegradable nanoparticles have effectively killed brain cancer cells and extended survival in animals.

For their studies, the Johns Hopkins team designed and tested a variety of nanoparticles made from different polymers, or plastics. When they found a good candidate that could deliver genes to rat brain cancer cells, they filled the nanoparticles with DNA encoding an enzyme, herpes simplex virus type 1 thymidine kinase (HSVtk), which turns a compound with little effect into a potent therapy that kills brain cancer cells. When combined with the compound, called ganciclovir, these loaded nanoparticles were 100 percent effective at killing glioma cells grown in laboratory dishes.

We then evaluated the system in rats with glioma and found that by using a method called intracranial convection-enhanced delivery, our nanoparticles could penetrate completely throughout the tumor following a single injection, says Jordan Green, Ph.D, associate professor of biomedical engineering and ophthalmology at Johns Hopkins. When combined with systemic administration of ganciclovir, rats with malignant glioma lived significantly longer than rats that did not receive this treatment. (Intracranial convection-enhanced delivery uses a pressure gradient to enhance diffusion throughout the tumor.)

In addition to revealing that biodegradable polymeric nanoparticles represent a promising mode of gene delivery for glioma, the findings show that nonviral DNA delivery of HSVtk combined with administration of ganciclovir has potent antitumor effects. To date, this type of system has only been used in humans with viral methods of gene delivery, of which the safety profiles are still heavily in debate, says Betty Tyler, associate professor of neurosurgery at Johns Hopkins. Additional studies are needed to see if these nanoparticles could also effectively deliver other antitumor genes for the treatment of brain tumors as well as systemic cancers.

Green also noted that additional safety and efficacy studies are needed before the treatment makes its way to the clinic. It also is unknown what the ideal gene combinations are that should be delivered using this nanoparticle delivery system, he says. We will move forward by evaluating this technology in additional brain cancer animal models.

Read the original:

New Nanoparticle Gene Therapy Strategy Effectively Treats Deadly Brain Cancer in Rats

Davos 2015 - The end of Blindness
http://www.weforum.org/ A discussion with leading researchers on progress in the fight to end blindness by 2020 Dimensions to be addressed: - Mapping the brain to replicate vision - Stem...

By: World Economic Forum

Go here to read the rest:

Davos 2015 - The end of Blindness - Video

Albany, NY (PRWEB) February 01, 2015

The new report is titled Recombinant Coagulation Factors 2015: Maturation of Recombinant Clotting Factor Pipeline and Emergence of Gene Therapy and Alternative Procoagulants and deals with historical statistics and future projections regarding the recombinant coagulation factors market. It gathers data from 2013 and the first three quarters of 2014 to analyze the development of the market through the two years. It focuses strongly on pipeline products in the market.

To get sample report with TOC Click Here: http://www.researchmoz.com/enquiry.php?type=sample&repid=241916

Recombinant coagulation factors are used in diseases such as hemophilia A and B, to bring about blood coagulation when the patients natural capacity to do so has been hampered. Market data for various classes of recombinant coagulation factors such as factors VII, VIII, and IX are analyzed in the research report, along with an examination of the development of other nascent and comparatively untouched substances and methods such as alternative procoagulants, immune tolerance-inducing agents, and gene therapeutics.

The report profiles the competitive landscape in detail and provides special attention to the impact of new products on the respective positions of major players of the market. This helps gain insight into the short-to-mid-term future of the market. Trends gaining strength in the market are also carefully examined, according to their potential impact on the market stats and competitive landscape.

To Browse a Full Report with TOC: http://www.researchmoz.us/recombinant-coagulation-factors-2015-maturation-of-recombinant-clotting-factor-pipeline-and-emergence-of-gene-therapy-and-alternative-procoagulants-report.html

The field of gene therapeutics, or gene therapy, is a strong emergent alternative to recombinant coagulation factors. New technologies in the gene therapy field are examined in detail, as are the major players intending to strengthen their presence in this sector. Keeping with this theme, the competitive advantages of alternative procoagulants and gene therapy are listed and analyzed.

The sales and market size of four major types of recombinant coagulation factors are analyzed in the report: rFVIII, rFIX, rFVII, and thrombin. Within the market analysis of rFVIII, specific medicines such as Helixate, Kogenate, Advate/Recombinate, etc. are analyzed deeper to understand their particular market size data. Likewise, the market data for medicines such as Benefix and Alprolix, which constitute the recombinant factor IX category, and NovoSeven and Coagil VII, which make up the recombinant factor VII category, are also examined in detail. The recombinant factor Thrombin is analyzed as a separate category.

Among pipeline projects, two distinct classes can be formed: wild-type recombinant factors and long-acting recombinant factors. Research into all types of recombinant factors, i.e., rFVIII, rFIX, and rFVII is ongoing to produce wild and long-acting varieties of each. The present market conditions for each are also described in the report, giving a clear idea of the trajectory from the present market conditions to the pipeline projects.

The report also profiles major pharmaceutical companies active in the recombinant coagulants market. These include giants such as Baxter, CSL, Novo Nordisk, Bayer HealthCare Pharmaceuticals, Biogen Idec, AstraZeneca, etc.

Follow this link:

Recombinant Coagulation Factors Pipeline Analysis to 2015 Now Available on ResearchMoz

JSB Market Research: Gene Therapy Immunology Insight
Gene Therapy Immunology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles...

By: Kalyani Roy

Read more here:

JSB Market Research: Gene Therapy Immunology Insight - Video

Included in top indexing databases and has an impact factor of 4.321! The journal website is hosted on http://www.nature.com that gets 8.4 million page views per month Over 69,000 table of contents registrants and 82,706 page views across the Gene Therapy web site on average Easy and quick online submission system Rapid and rigorous peer review Advanced Article Preview (AAP) feature to be available from early March 2015 to all accepted original and review article authors. Accepted articles to be available online within 72 hours of acceptance into production! For further information on AAP please refer to About accepted article preview section Free manuscript deposition service to Pub Med Central on behalf of non-open access authors We regularly promote content alongside that of the Nature branded titles on our subject pages and in collections as well as via social media We also have a number of regional websites reaching a wide and varied audience demographic http://www.nature.com/regions Free online issue

Volume 22, No 1 January 2015 ISSN: 0969-7128 EISSN: 1476-5462

2013 Impact Factor 4.321* 70/290 Biochemistry & Molecular Biology 22/159 Biotechnology & Applied Microbiology 33/161 Genetics & Heredity 25/121 Medicine, Research & Experimental

Editors: J Glorioso, USA N Lemoine, UK

*2013 Journal Citation Reports Science Edition (Thomson Reuters, 2014)

Download the presentation from our How to Get Published Session. (281 kB)

Open

Gene Therapy now offers authors the option to publish their articles with immediate open access upon publication. Open access articles will also be deposited on PubMed Central at the time of publication and will be freely available immediately. Find out more from our FAQs page.

Reviews by top researchers in the field. See the recent Progress and Prospects articles.

Essential topics explored in depth in Gene Therapy Special Issues.

Go here to see the original:

Gene Therapy - Nature Publishing Group : science journals ...

Gene Therapy Pioneer Ted Friedman Awarded Japan Prize
Theodore Friedmann, MD, professor in the Department of Pediatrics at University of California, San Diego School of Medicine has been named a 2015 recipient of the Japan Prize, a prestigious...

By: UC San Diego Health System

Read the rest here:

Gene Therapy Pioneer Ted Friedman Awarded Japan Prize - Video

Prof Wang Bin - Bio Gene Therapy

By: Kelvin Kwek CT

Read more:

Prof Wang Bin - Bio Gene Therapy - Video

Anna David, Prenatal Cell and Gene Therapy
Anna David, Prenatal Cell and Gene Therapy (Research Department of Maternal and Fetal Medicine, UCL EGA Institute for Women #39;s Health) talks about her group #39;s...

By: UCL EGA Institute for Women #39;s Health

Visit link:

Anna David, Prenatal Cell and Gene Therapy - Video

Dr. Theodore Friedmann is a longtime faculty member at UC San Diego and a pioneer in gene therapy. / photo by Nelvin C. Cepeda * U-T San Diego

Dr. Theodore Friedmann, a pioneer in the booming field of gene therapy, has been named a 2015 winner of the prestigious Japan Prize.

A pediatrician-turned-researcher at UC San Diego, Friedmann is renowned for demonstrating in the lab that it is possible to correct a genetic defect by adding a functional gene to defective cells, a feat he and colleagues accomplished in 1968. Since then, Friedmann has been guiding the young science through controversies, ethical challenges and setbacks.

Friedmann shares the prize in "medical science and medicinal science" with Dr. Alain Fischer of the Necker Hospital in Paris, France. Fischer helped demonstrate gene therapy's clinical ability to treat a genetic immune deficiency that makes patients extremely vulnerable to infections.

Along with the recognition, Friedmann and Fischer will split a $416,600 award, a certificate and gold medal. There's also the prospect of future recognition: several Japan Prize winners have gone on to win the Nobel Prize.

Friedmann is known not only as a scientist who demonstrated gene therapy is possible, but as a thinker who has dampened the waves of excessive exuberance and despondency that often accompanies the passage of research discoveries into therapies. He has also cautioned his fellow scientists to approach gene therapy with great caution.

In 1972, Friedmann co-authored an influential article in the journal Science, "Gene therapy for human genetic disease?" proposing a program of research advancement and safety precautions with an eye to eventual therapy. In February, 2010, he coauthored an article in Science about the potential use of performance-enhancing "gene doping" in sports.

Those who didn't heed Friedmann's warnings ran into trouble. For example, in 1999 gene therapy patient Jesse Gelsinger, 18, died due to an immune reaction. Gelsinger had a mild form of a genetically caused liver disease, controlled with drugs and diet. He was enrolled to test a treatment to be used in babies with a fatal form of the disease. But Gelsinger himself had little to gain.

A mountain of bad publicity threatened to sink the field. The New York Times wrote about "The Biotech Death of Jesse Gelsinger." As a consequence, other new forms of therapy, such as stem cell treatments, have progressed more slowly to avoid a repeat.

The Gelsinger disaster has receded into the background, as safer forms of gene therapy edge closer to becoming an accepted part of medicine. Forms of gene therapy are now being tested in clinical trials to treat such different diseases as cancer, sickle cell anemia and HIV, with impressive results.

Read the original here:

Friedmann wins Japan Prize for gene therapy

Contact Information

Available for logged-in reporters only

Newswise Theodore Friedmann, MD, professor in the Department of Pediatrics at University of California, San Diego School of Medicine was named today one of three recipients of the 2015 Japan Prize, a prestigious international award honoring laureates whose original and outstanding achievements in science and technology have advanced the frontiers of knowledge and served the cause of peace and prosperity for mankind.

Friedmann is being recognized for his pioneering research and contributions to the development of gene therapy, a new field of medicine which in significant ways originated at UC San Diego. The sponsoring Japan Prize Foundation describes Friedmann as the father of gene therapy.

Sharing the 2015 Japan Prize in the field of medical science and medicinal science with Friedman is Alain Fischer, MD, PhD, director of immunology at the Necker Hospital in Paris, France. Fischer is credited with demonstrating the clinical efficacy of gene therapy by successfully treating children suffering from a severe genetic disorder that renders them extremely vulnerable to infections.

The third 2015 Japan Prize laureate is Yutaka Takahasi, PhD, professor emeritus at the University of Tokyo, who is being honored in the field of resources, energy and social infrastructure for his contributions to river basin management and reducing water-related disasters.

Each laureate will receive a certificate of recognition and commemorative gold medal. A cash award of approximately $416,600 will also be given to each prize field. Since its inception in 1985, 83 laureates from 13 countries have received the Japan Prize in a variety of fields and disciplines. Several have subsequently become Nobel Prize laureates as well.

In 1972, Friedmann, then a visiting scientist at the Salk Institute for Biological Sciences in La Jolla, and Richard Roblin, also at the Salk Institute, published a foundational article in the field, a paper in the journal Science under the heading Gene therapy for human genetic disease?

The idea of gene therapy, which quickly captured the public imagination, was fueled by its appealingly straightforward approach and what Friedmann has described as its obvious correctness: Disarm a potentially pathogenic virus to make it benign. Stuff these viral particles with normal DNA. Then inject them into patients carrying abnormal genes where they will deliver their therapeutic cargoes inside the defective target cells. In theory, the good DNA replaces or corrects the abnormal function of the defective genes, rendering previously impaired cells whole, normal and healthy. End of disease.

Its not quite that simple, of course, something Friedmann and Roblin cautioned in their 1972 paper. Despite progress in the understanding of cellular functions, the roles of DNA and a series of experimental and clinical advances, the history of gene therapy has been marked by distinct highs and lows.

Go here to read the rest:

Friedmann Named 2015 Japan Prize Winner

DUBLIN, January 27, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/pfd99m/recombinant) has announced the addition of the "Recombinant Coagulation Factors 2015: Maturation Of Recombinant Clotting Factor Pipeline And Emergence Of Gene Therapy And Alternative Procoagulants" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

A Pipeline Landscape Analysis and Comparative Assessment of Key Players

This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in development are presented in details not only for recombinant coagulation factors VIII, IX and VII, but also for emerging alternative procoagulants, gene therapeutics and immune tolerance inducing agents.

The competitve landscape of classical recombinant coagulation factors and of new emerging treatment modalities of hemophilia and other severe bleeding orders is analyzed. The emergence of new treatment modalities brings many new stakeholders to the field of hemophilia. Among them are the established hemophilia portofolio companies, but also new entrants from Big Pharma and Big Biotech, specialty pharmaceutical companies, biosimilar companies, and new technology providers as half-life prolongation technologies are no longer in the focus of major interest.

A short- to mid-term outlook into the field is provided and the trends driving the future of this therapeutic segment are identified and described. Preparation of this report is based on information stored in La Merie Publishing's proprietary data base and news archive, on scientific literature, and on corporate disclosures. The data are presented, analyzed and assessed in a comprehensive manner by an experienced author with an independent view writing the fifth edition of this report series.

Key Topics Covered:

1. Executive Summary

2. Recombinant Coagulation Factor Markets 2.1 Recombinant Factor VIII (rFVIII) Product Sales and Market Size 2.2 Recombinant Factor IX (rFIX) Product Sales and Market Size 2.3 Recombinant Factor VII (rFVII) Product Sales and Market Size 2.4 Recombinant Thrombin Product Sales and Market Size 2.5 Total Recombinant Coagulation Factor Market Size

3. Pipeline Update of Recombinant Coagulation Factors 3.1 Factor VIII Pipeline Changes and Drug Profile Updates 3.2 Factor IX Pipeline Changes and Drug Profile Updates 3.3 Factor VII Pipeline Changes and Drug Profile Updates 3.4 Pipeline Update for Other Recombinant Coagulation Factors 3.5 Pipeline Update for Alternative Procoagulants 3.6 Pipeline Update for Gene & Cell Therapy 3.7 Immune Tolerance Inducing (ITI) Agents

View original post here:

Recombinant Coagulation Factors 2015: Maturation Of Recombinant Clotting Factor Pipeline And Emergence Of Gene Therapy ...

lily and america gene therapy

By: America Evans

Read this article:

lily and america gene therapy - Video

Gene therapy trial for thalassemia at Royal Prince Alfred Hospital
A world first gene therapy trial is currently underway at Royal Prince Alfred Hospital with the potential to cure patients living with thalassemia. Patient Stacey Wong has required long frequent...

By: SydneyLHD

Visit link:

Gene therapy trial for thalassemia at Royal Prince Alfred Hospital - Video

Flagship Journal Current Gene Therapy
A short promotional video of Bentham Science High Impact Journal Current Gene Therapy.

By: Bentham Science Publishers

Follow this link:

Flagship Journal Current Gene Therapy - Video

Aarkstore -Gene Therapy Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape
Gene Therapy Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles core insights,...

By: sangam Jain

Here is the original post:

Aarkstore -Gene Therapy Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape - Video

Switzerland: The Elixir of Life? Scientists COULD make you live to 120!
Researchers from Bern University may have found gene therapy that can extend life by 60 percent. At the moment, the experiment is limited to fruit flies, who have just been given their third...

By: RuptlyTV

Read the original:

Switzerland: The Elixir of Life? Scientists COULD make you live to 120! - Video

He added that one passage in the Bible, the Magnificat or the Song of Mary is so revolutionary he was surprised it was not banned as un-American during the McCarthy era.

His comments came as he took part in a conference at the Trinity Wall Street church in New York discussing the idea of the common good.

In an address on whether inequality matters, he argued that a message of basic equality can be traced through the Bible from the Garden of Eden to the New Testament accounts of the early church.

He said that although wealth is, in some parts of the Bible, viewed as a blessing, in others it is linked to corruption but that overall there was no right to be rich.

He added that some people had labelled passages in the Book of Acts, talking about wealth being shared between the early Christians, as communist but said this was untrue because the common ownership in the Bible was voluntary not obligatory.

Looking ahead to the next 40 years, he said: In an era in which we will see the growth of technologies like Artificial Intelligence and gene therapies, economists like Lawrence Summers foresee growing inequalities between the small minority who can maximise the benefits of new technology and the large majority who will see only stagnation in income.

We face the challenge of a society in which inequality of education or health or opportunity becomes and continues to be a life sentence to poverty.

And that is the challenge which is exactly the one that we find the prophets so concerned about.

Mr Summers wrote last year that the devastating consequences of robots and technologies like 3D printing replacing human workers would become the main story in economics and politics in years to come.

The Archbishop said: The theological understanding is that wealth is always in danger of corrupting its holders in most cases, and the corrupted become too powerful.

View post:

Welby: Artificial Intelligence and gene therapy could hand super-rich ever more power